Nuclear receptor PPAR and hepatology: Pathophysiological and therapeutical aspects;Récepteurs nucléaires PPAR et hépatologie : implications physiopathologiques et thérapeutiques

Gastroenterologie Clinique et Biologique

Volumn 32, Issue 3, 2008, Pages 339-350

  Dharancy, S ^a,b,c   Louvet, A ^a,b,c   Hollebecque, A ^a,b,c   Desreumaux, P ^a,b,c   Mathurin, P ^a,b,c   Dubuquoy, L ^a,b,c  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TESAGLITAZAR;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR SYSTEM; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CHRONIC LIVER DISEASE; FATTY LIVER; GLUCOSE METABOLISM; IN VITRO STUDY; INFLAMMATION; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; SHORT SURVEY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; HUMANS; INFLAMMATION; LIVER DISEASES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR GAMMA; THIAZOLES; THIAZOLIDINEDIONES;

EID: 50349102093     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2008.01.029     Document Type: Short Survey

References (109)

1. Robinson-Rechavi M., Carpentier A.S., Duffraisse M., and Laudet V. How many nuclear hormone receptors are there in the human genome?. Trends Genet 17 (2001) 554-556
2. Maglich J.M., Sluder A., Guan X., Shi Y., McKee D.D., Carrick K., et al. Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans and Drosophila genomes. Genome Biol 2 (2001) 29
3. Enmark E., and Gustafsson J.A. Comparing nuclear receptors in worms, flies and humans. Trends Pharmacol Sci 22 (2001) 611-615
4. Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P., et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320 (1986) 134-139
5. Hollenberg S.M., Weinberger C., Ong E.S., Cerelli G., Oro A., Lebo R., et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 318 (1985) 635-641
6. Escher P., and Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 448 (2000) 121-138
7. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999;97:161-3.
8. Olefsky J.M. Nuclear receptor minireview series. J Biol Chem 276 (2001) 36863-36864
9. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., et al. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
10. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., and Evans R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358 (1992) 771-774
11. Glass C.K., and Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 6 (2006) 44-55
12. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
13. Willson T.M., and Wahli W. Peroxisome proliferator-activated receptor agonists. Curr Opin Chem Biol 1 (1997) 235-241
14. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
15. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
16. Schopfer F.J., Lin Y., Baker P.R., Cui T., Garcia-Barrio M., Zhang J., et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci USA 102 (2005) 2340-2345
17. Fagerberg B., Edwards S., Halmos T., Lopatynski J., Schuster H., Stender S., et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48 (2005) 1716-1725
18. Kendall D.M., Rubin C.J., Mohideen P., Ledeine J.M., Belder R., Gross J., et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29 (2006) 1016-1023
19. Ye J.M., Iglesias M.A., Watson D.G., Ellis B., Wood L., Jensen P.B., et al. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 284 (2003) E531-E540
20. Nissen S.E., Wolski K., and Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 (2005) 2581-2586
21. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46 (1997) 1319-1327
22. Tugwood J.D., Holden P.R., James N.H., Prince R.A., and Roberts R.A. A peroxisome proliferator-activated receptor-alpha (PPARalpha) cDNA cloned from guinea-pig liver encodes a protein with similar properties to the mouse PPARalpha: implications for species differences in responses to peroxisome proliferators. Arch Toxicol 72 (1998) 169-177
23. Jalouli M., Carlsson L., Ameen C., Linden D., Ljungberg A., Michalik L., et al. Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: influence of pituitary and gonadal hormones. Endocrinology 144 (2003) 101-109
24. Miyahara T., Schrum L., Rippe R., Xiong S., Yee Jr. H.F., Motomura K., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275 (2000) 35715-35722
25. Dharancy S., Malapel M., Perlemuter G., Roskams T., Cheng Y., Dubuquoy L., et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 128 (2005) 334-342
26. Hoekstra M., Kruijt J.K., Van Eck M., and Van Berkel T.J. Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. J Biol Chem 278 (2003) 25448-25453
27. Hoekstra M., Out R., Kruijt J.K., Van Eck M., and Van Berkel T.J. Diet induced regulation of genes involved in cholesterol metabolism in rat liver parenchymal and Kupffer cells. J Hepatol 42 (2005) 400-407
28. Peters J.M., Rusyn I., Rose M.L., Gonzalez F.J., and Thurman R.G. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis 21 (2000) 823-826
29. Marra F., Efsen E., Romanelli R.G., Caligiuri A., Pastacaldi S., Batignani G., et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119 (2000) 466-478
30. Galli A., Crabb D.W., Ceni E., Salzano R., Mello T., Svegliati-Baroni G., et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122 (2002) 1924-1940
31. Hellemans K., Michalik L., Dittie A., Knorr A., Rombouts K., De Jong J., et al. Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124 (2003) 184-201
32. Colville-Nash P., Willis D., Papworth J., Freemantle C., Lam C., Andrews G., et al. The peroxisome proliferator-activated receptor alpha activator, Wy14,643, is anti-inflammatory in vivo. Inflammopharmacology 12 (2005) 493-504
33. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49 (2000) 497-505
34. Delerive P., Gervois P., Fruchart J.C., and Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 275 (2000) 36703-36707
35. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
36. Kockx M., Gervois P.P., Poulain P., Derudas B., Peters J.M., Gonzalez F.J., et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood 93 (1999) 2991-2998
37. Di Paola R., Esposito E., Mazzon E., Genovese T., Muia C., Crisafulli C., et al. Absence of peroxisome proliferators-activated receptors (PPAR)alpha enhanced the multiple organ failure induced by zymosan. Shock 26 (2006) 477-484
38. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., and Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384 (1996) 39-43
39. Peters J.M., Hennuyer N., Staels B., Fruchart J.C., Fievet C., Gonzalez F.J., et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 272 (1997) 27307-27312
40. Anderson S.P., Yoon L., Richard E.B., Dunn C.S., Cattley R.C., and Corton J.C. Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice. Hepatology 36 (2002) 544-554
41. Hashimoto T., Cook W.S., Qi C., Yeldandi A.V., Reddy J.K., and Rao M.S. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 275 (2000) 28918-28928
42. Gervois P., Kleemann R., Pilon A., Percevault F., Koenig W., Staels B., et al. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem 279 (2004) 16154-16160
43. Gervois P., Vu-Dac N., Kleemann R., Kockx M., Dubois G., Laine B., et al. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem 276 (2001) 33471-33477
44. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., and Padula S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 164 (2000) 1364-1371
45. Cunard R., DiCampli D., Archer D.C., Stevenson J.L., Ricote M., Glass C.K., et al. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J Immunol 169 (2002) 6806-6812
46. Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., et al. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 168 (2002) 2795-2802
47. Cunard R., Eto Y., Muljadi J.T., Glass C.K., Kelly C.J., and Ricote M. Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J Immunol 172 (2004) 7530-7536
48. Uchimura K., Nakamuta M., Enjoji M., Irie T., Sugimoto R., Muta T., et al. Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology 33 (2001) 91-99
49. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
50. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 275 (2000) 4541-4544
51. Marx N., Kehrle B., Kohlhammer K., Grub M., Koenig W., Hombach V., et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 90 (2002) 703-710
52. Kosuge H., Haraguchi G., Koga N., Maejima Y., Suzuki J., and Isobe M. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation 113 (2006) 2613-2622
53. Friedman S.L. Liver fibrosis -- from bench to bedside. J Hepatol 38 (2003) S38-S53
54. Friedman S.L. Hepatic stellate cells. Prog Liver Dis 14 (1996) 101-130
55. Hazra S., Krishna V., Chatterjee K., Rippe R.A., and Tsukamoto H. PPARγ dependent regulation of hepatic stellate cells (abstract). Hepatology 36 (2002) 255A
56. Kon K., Ikejima K., Hirose M., Yoshikawa M., Enomoto N., Kitamura T., et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 291 (2002) 55-61
57. Marra F., Robino G., Pastacaldi S., Pinzani M., Gentilini P., and Parola M. Troglitazone inhibits the development of experimental fibrosis in the rat (abstract). Hepatology 36 (2002) 250A
58. Rao M.S., and Reddy J.K. Peroxisome proliferation and hepatocarcinogenesis. Carcinogenesis 8 (1987) 631-636
59. Reddy J.K., and Rao M.S. Oxidative DNA damage caused by persistent peroxisome proliferation: its role in hepatocarcinogenesis. Mutat Res 214 (1989) 63-68
60. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15 (1995) 3012-3022
61. Davidson M.H., Armani A., McKenney J.M., and Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 99 (2007) 3C-18C
62. Holden P.R., and Tugwood J.D. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J Mol Endocrinol 22 (1999) 1-8
63. Palmer C.N., Hsu M.H., Griffin K.J., Raucy J.L., and Johnson E.F. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 53 (1998) 14-22
64. Morimura K., Cheung C., Ward J.M., Reddy J.K., and Gonzalez F.J. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 27 (2006) 1074-1080
65. Woodyatt N.J., Lambe K.G., Myers K.A., Tugwood J.D., and Roberts R.A. The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis 20 (1999) 369-372
66. Rodriguez C., Noe V., Cabrero A., Ciudad C.J., and Laguna J.C. Differences in the formation of PPARalpha-RXR/acoPPRE complexes between responsive and nonresponsive species upon fibrate administration. Mol Pharmacol 58 (2000) 185-193
67. Schaefer K.L., Wada K., Takahashi H., Matsuhashi N., Ohnishi S., Wolfe M.M., et al. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 65 (2005) 2251-2259
68. Yu J., Qiao L., Zimmermann L., Ebert M.P., Zhang H., Lin W., et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 43 (2006) 134-143
69. Rumi M.A., Sato H., Ishihara S., Kawashima K., Hamamoto S., Kazumori H., et al. Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. Br J Cancer 84 (2001) 1640-1647
70. Koga H., Sakisaka S., Harada M., Takagi T., Hanada S., Taniguchi E., et al. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33 (2001) 1087-1097
71. Toyoda M., Takagi H., Horiguchi N., Kakizaki S., Sato K., Takayama H., et al. A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50 (2002) 563-567
72. Mueller E., Smith M., Sarraf P., Kroll T., Aiyer A., Kaufman D.S., et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97 (2000) 10990-10995
73. Kulke M.H., Demetri G.D., Sharpless N.E., Ryan D.P., Shivdasani R., Clark J.S., et al. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 8 (2002) 395-399
74. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270 (1995) 12953-12956
75. Watkins P.B., and Whitcomb R.W. Hepatic dysfunction associated with troglitazone. N Engl J Med 338 (1998) 916-917
76. Lebovitz H.E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 18 Suppl. 2 (2002) S23-S29
77. Lebovitz H.E., Kreider M., and Freed M.I. Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25 (2002) 815-821
78. FDA Issues Safety Alert on Avandia. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01636.html 25/08/2007.
79. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
80. Home P.D., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Jones N.P., et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med 357 (2007) 28-38
81. Uto H., Nakanishi C., Ido A., Hasuike S., Kusumoto K., Abe H., et al. The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet. Hepatol Res 32 (2005) 235-242
82. Leclercq I.A., Lebrun V.A., Starkel P., and Horsmans Y.J. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. Lab Invest 87 (2007) 56-65
83. Kawaguchi K., Sakaida I., Tsuchiya M., Omori K., Takami T., and Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 315 (2004) 187-195
84. Caldwell S.H., Hespenheide E.E., Redick J.A., Iezzoni J.C., Battle E.H., and Sheppard B.L. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96 (2001) 519-525
85. Azuma T., Tomita K., Kato S., Adachi M., Inokuchi S., Kitamura N., et al. A pilot study of a thiazolidinedione, pioglitazone, in nonalcoholic steatohepatitis (abstract). Hepatology 36 (2002) 406A
86. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
87. Sanyal A.J., Mofrad P.S., Contos M.J., Sargeant C., Luketic V.A., Sterling R.K., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2 (2004) 1107-1115
88. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
89. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
90. Galli A., Pinaire J., Fischer M., Dorris R., and Crabb D.W. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. J Biol Chem 276 (2001) 68-75
91. Galli A., Ceni E., Crabb D.W., Mello T., Salzano R., Surrenti C., et al. Acetaldehyde inhibits peroxisome proliferator-activated receptor gamma (PPARγ) transcriptional activity in hepatic stellate cells. A MAPK/PKCdelta-dependent mechanism (abstract). Hepatology 36 (2002) 250A
92. Ceni E., Crabb D.W., Foschi M., Mello T., Tarocchi M., Patussi V., et al. Acetaldehyde inhibits PPARgamma via H2O2-mediated c-Abl activation in human hepatic stellate cells. Gastroenterology 131 (2006) 1235-1252
93. Wan Y.J., Morimoto M., Thurman R.G., Bojes H.K., and French S.W. Expression of the peroxisome proliferator-activated receptor gene is decreased in experimental alcoholic liver disease. Life Sci 56 (1995) 307-317
94. Zhao C.Y., Jiang L.L., Li L., Deng Z.J., Liang B.L., and Li J.M. Peroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease. World J Gastroenterol 10 (2004) 1329-1332
95. Fischer M., You M., Matsumoto M., and Crabb D.W. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 278 (2003) 27997-28004
96. Nanji A.A., Dannenberg A.J., Jokelainen K., and Bass N.M. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation. J Pharmacol Exp Ther 310 (2004) 417-424
97. Enomoto N., Takei Y., Hirose M., Konno A., Shibuya T., Matsuyama S., et al. Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J Pharmacol Exp Ther 306 (2003) 846-854
98. Ohata M., Suzuki H., Sakamoto K., Hashimoto K., Nakajima H., Yamauchi M., et al. Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha. Alcohol Clin Exp Res 28 (2004) 139S-144S
99. Tomita K., Azuma T., Kitamura N., Nishida J., Tamiya G., Oka A., et al. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 126 (2004) 873-885
100. Yamaguchi A., Tazuma S., Nishioka T., Ohishi W., Hyogo H., Nomura S., et al. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 50 (2005) 1361-1371
101. Serfaty L., Andreani T., Giral P., Carbonell N., Chazouilleres O., and Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 34 (2001) 428-434
102. Ratziu V., Heurtier A., Bonyhay L., Poynard T., and Giral P. Review article: an unexpected virus-host interaction--the hepatitis C virus-diabetes link. Aliment Pharmacol Ther 22 Suppl. 2 (2005) 56-60
103. Moucari R., Marcellin P., and Asselah T. Stéatose au cours de l'hépatite chronique C : rôle de l'insulino-résistance et des facteurs viraux. Gastroenterol Clin Biol 31 (2007) 643-654
104. de Gottardi A., Pazienza V., Pugnale P., Bruttin F., Rubbia-Brandt L., Juge-Aubry C.E., et al. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 23 (2006) 107-114
105. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11 (1997) 779-791
106. Kurihara T., Niimi A., Maeda A., Shigemoto M., and Yamashita K. Study of effectiveness of bezafibrate in the treatment of chronic hepatitis C. Am J Gastroenterol 96 (2001) 1659-1660
107. Fujita N., Kaito M., Tanaka H., Horiike S., and Adachi Y. Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis C. Am J Gastroenterol 99 (2004) 2280
108. Pioglitazone in Hepatitis C. http://clinicaltrials.gov/show/NCT00189163 25/08/2007
109. Rakic B., Sagan S.M., Noestheden M., Belanger S., Nan X., Evans C.L., et al. Peroxisome proliferator-activated receptor alpha antagonism inhibits hepatitis C virus replication. Chem Biol 13 (2006) 23-30